Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Current Deferred Revenue (2024 - 2025)

Historic Current Deferred Revenue for Day One Biopharmaceuticals (DAWN) over the last 2 years, with Q3 2025 value amounting to $2.3 million.

  • Day One Biopharmaceuticals' Current Deferred Revenue rose 5848.15% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 5848.15%. This contributed to the annual value of $1.6 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Current Deferred Revenue of $2.3 million as of Q3 2025, which was up 5848.15% from $1.8 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' Current Deferred Revenue's 5-year high stood at $2.3 million during Q3 2025, with a 5-year trough of $1.5 million in Q3 2024.